Arrowhead Pharmaceuticals
Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.
$84.80
After-hours close−0.11 (−0.13%)
At close$84.91(−4.15%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.53 | — | — |
| Aug 2026 | −$1.28 | −$1.36 | −6.3% |
| May 2026 | −$1.18 | −$0.93 | +21.2% |
| Feb 2026 | $0.60 | $0.22 | −63.3% |
| Nov 2025 | −$0.11 | −$0.18 | −61.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Dec 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Dec 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Dec 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 24, 2026 | −$1.53 | — | — | $71.8M | — | — |
| Aug 4, 2026 | −$1.28 | −$1.36 | −6.3% | $44.2M | $75.3M | +70.4% |
| May 7, 2026 | −$1.18 | −$0.93 | +21.2% | $73.8M | $73.7M | −0.1% |
| Feb 5, 2026 | $0.60 | $0.22 | −63.3% | $213.9M | $264.0M | +23.4% |
| Nov 25, 2025 | −$0.11 | −$0.18 | −61.3% | $175.3M | $256.5M | +46.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 12, 2025 | ||||||
| Feb 10, 2025 | ||||||
| Nov 26, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 6, 2024 | ||||||
| Nov 29, 2023 | ||||||
| Aug 7, 2023 | ||||||
| May 2, 2023 | ||||||
| Feb 6, 2023 | ||||||
| Nov 28, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 10, 2022 | ||||||
| Feb 2, 2022 | ||||||
| Nov 22, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 4, 2021 | ||||||
| Feb 4, 2021 | ||||||
| Nov 23, 2020 | ||||||
| Aug 5, 2020 | ||||||
| May 7, 2020 | ||||||
| Feb 5, 2020 | ||||||
| Nov 25, 2019 | ||||||
| Aug 5, 2019 | ||||||
| May 8, 2019 | ||||||
| Feb 7, 2019 | ||||||
| Dec 11, 2018 | ||||||
| Aug 7, 2018 | ||||||
| May 8, 2018 | ||||||
| Feb 9, 2018 | ||||||
| Dec 12, 2017 | ||||||
| Aug 3, 2017 | ||||||
| May 3, 2017 | ||||||
| Feb 6, 2017 | ||||||
| Dec 14, 2016 | ||||||
| Aug 9, 2016 | ||||||
| May 10, 2016 | ||||||
| Feb 9, 2016 | ||||||
| Dec 14, 2015 | ||||||
| Aug 4, 2015 | ||||||